{"nctId":"NCT00337727","briefTitle":"Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)","startDateStruct":{"date":"2007-01-01","type":"ACTUAL"},"conditions":["Chemotherapy-Induced Nausea and Vomiting"],"count":848,"armGroups":[{"label":"1","type":"OTHER","interventionNames":["Drug: aprepitant","Drug: Comparator: ondansetron","Drug: Comparator: dexamethasone","Drug: Comparator; Placebo (unspecified)"]},{"label":"2","type":"OTHER","interventionNames":["Drug: Comparator: ondansetron","Drug: Comparator: dexamethasone","Drug: Comparator: fosaprepitant dimeglumine","Drug: Comparator; Placebo (unspecified)"]}],"interventions":[{"name":"aprepitant","otherNames":["MK0869"]},{"name":"Comparator: ondansetron","otherNames":["Zofran®"]},{"name":"Comparator: dexamethasone","otherNames":["DEXAMETHASONE TABLETS USP"]},{"name":"Comparator: fosaprepitant dimeglumine","otherNames":["EMEND®"]},{"name":"Comparator; Placebo (unspecified)","otherNames":[]},{"name":"Comparator; Placebo (unspecified)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients will be naive to emetogenic chemotherapy with histologically or cytologically confirmed malignant disease scheduled to receive a single dose of moderately emetogenic chemotherapy on study day 1\n* Karnofsky score of 60 or greater\n\nExclusion Criteria:\n\n* Patient is scheduled to receive any dose of cisplatin\n* Patient will receive abdominal or pelvic radiation a week prior and up to 6 days after initiation of chemotherapy\n* Any allergies to study drug or antiemetics\n* Taking CYP3A4 substrates/prohibited medication\n* Significant medical or mental conditions\n* Abnormal laboratory values (platelets, absolute neutrophils, AST, ALT, bilirubin or creatinine).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients Who Reported No Vomiting","description":"The number of patients who reported No Vomiting in the overall phase in Cycle\n\n1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"324","spread":null},{"groupId":"OG001","value":"252","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Who Reported Complete Response","description":"The number of patients who reported Complete Response (no vomiting and no use of rescue medication) in the overall phase in Cycle 1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"292","spread":null},{"groupId":"OG001","value":"229","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":430},"commonTop":["Headache","Constipation","Fatigue","Diarrhoea","Anorexia"]}}}